Investment Analysts’ Weekly Ratings Updates for Illumina (ILMN)

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

• 7/18/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Illumina had its price target raised by Leerink Partners from $175.00 to $210.00. They now have an “outperform” rating on the stock.
• 7/15/2026 – Illumina had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $140.00 to $190.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 7/1/2026 – Illumina had its price target raised by Piper Sandler from $170.00 to $200.00. They now have an “overweight” rating on the stock.
• 6/29/2026 – Illumina had its price target raised by Guggenheim from $180.00 to $200.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Illumina is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $185.00 price target on the stock.
• 6/25/2026 – Illumina was upgraded by Sanford C. Bernstein to “hold”.
• 6/24/2026 – Illumina had its price target raised by Barclays PLC from $122.00 to $145.00. They now have an “underweight” rating on the stock.
• 6/10/2026 – Illumina was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $185.00 price target on the stock, up from $125.00.
• 6/3/2026 – Illumina was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 6/1/2026 – Illumina had its price target raised by Guggenheim from $170.00 to $180.00. They now have a “buy” rating on the stock.

Insider Transactions at Illumina

In other news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the sale, the insider owned 20,953 shares of the company’s stock, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last 90 days. 2.90% of the stock is owned by corporate insiders.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.